‘Liquid DNA Biopsy’ Helps to Spot Ovarian Cancer Patients at Risk of Relapse

‘Liquid DNA Biopsy’ Helps to Spot Ovarian Cancer Patients at Risk of Relapse
Ovarian cancer relapses may be effectively monitored and, possibly, detected early by analyzing patients' DNA in blood samples, Mayo Clinic researchers report in the study, “Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-Free DNA from Ovarian Cancers,” published in the journal Science Reports. When tumor cells are dying, they release DNA into the blood stream that differs from the DNA derived from non-cancerous tissue. This DNA "signature" can be used as a "liquid biopsy" biomarker, the researchers said. Using blood samples collected before and after surgery, and next-generation whole genome sequencing (known as mate-pair sequencing),they compared DNA from 10 patients' liquid blood biopsies to DNA from tumor tissue samples. "In this study, the blood drawn before and after surgery and the surgical tissue was used to identify DNA fragments with abnormal junctions that can only be seen in this patient's tumor DNA," George Vasmatzis, PhD, with the Department of Laboratory Medicine and Pathology, said in a press release. Before surgery, tumor-specific DNA fragments were detected in the blood of eight patients. After surgery, three of these eight still had detectable levels of circulating tumor DNA consistent with the presence of disease. The other five patients had no tumor DNA detectable in the post-surgical blood collection, which was also consistent with their lack of detectable disease. Detection of circulating tumor DNA after surgery warns for a closer patient follow-up to avoid recu
Subscribe or to access all post and page content.

Tagged , , , .

Chris Comish serves as the Publisher of the website, and is responsible for directing the editorial focus as well as putting the finishing touches on many featured articles.

Leave a Comment

Your email address will not be published. Required fields are marked *